NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Supreme Court Of India
    Central Bureau Of Investigation (CBI)
    Indian Army
    Indian Railways
    Indian Air Force
    NewsBytes
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / Affordable COVID-19 vaccine by January 2021, promises SII's Adar Poonawalla
    India

    Affordable COVID-19 vaccine by January 2021, promises SII's Adar Poonawalla

    Affordable COVID-19 vaccine by January 2021, promises SII's Adar Poonawalla
    Written by Shalini Ojha
    Nov 05, 2020, 02:24 pm 3 min read
    Affordable COVID-19 vaccine by January 2021, promises SII's Adar Poonawalla

    Adar Poonawalla, the CEO of Serum Institute of India, said that the vaccine against coronavirus will be available in India by January 2021, two months from now, provided that the government gives approvals on time. SII has partnered with UK pharma giant AstraZeneca to mass produce the vaccine being developed by the prestigious University of Oxford. Here's more on what he said.

    Success of trials will dictate the future of vaccine

    Speaking to Mint, Poonawalla said the availability of the vaccine, obviously, depends on the results from trials. "Based on the success of the trials in India and the United Kingdom, and if approvals from regulatory bodies are in place in time, then we can expect the vaccine to be available in India by January 2021, only if it's proven immunogenic and efficacious," he added.

    No concerns related to Covishield so far: Poonawalla

    "The current data pertaining to the trials show that there are no immediate concerns pertaining to Covishield (the vaccine). So far, thousands of people have had it in India and abroad with no safety concerns," Poonawalla stressed.

    Results from trials gave hope to a ripped apart globe

    Oxford's product is being dubbed as the frontrunner in the vaccine race after it was known that its doses provided double protection against the disease by generating virus-attacking T-cells. The vaccine is being tested across 17 sites in India. In phase II, nearly 1,600 participants, aged between 18 to 55, were administered doses. The third stage trials have also started at some sites.

    Poonawalla assured the vaccine will be affordable

    SII's deal with AstraZeneca positions India in a better place, as it means the country will get the vaccine sooner than others. However, there have been some concerns about the vaccine's cost. When asked about this, Poonawalla said, "We are in conversation with the government regarding the pricing. We are certain that it will be affordable for all."

    Does government have Rs. 80,000 crore ready, Poonawalla had asked

    However, in September, Poonawalla had asked if the government has Rs. 80,000 crore ready within the next one year for vaccine distribution. "Will the government of India have 80,000 crores available, over the next one year? Because that's what @MoHFW_INDIA needs, to buy and distribute the vaccine to everyone in India. This is the next concerning challenge we need to tackle," he had tweeted.

    We don't agree with Poonawalla's calculation: Centre

    Subsequently, the government said it did not agree with Poonawalla's calculation. Asserting that the SII boss clarified his statement soon, Union Health Secretary Rajesh Bhushan said, "We do not agree with the calculation of Rs. 80,000 crore." He said Centre formed a National Expert Group on Vaccine Administration to look into all things vaccine related. The body also pondered about the money needed.

    Centre claimed it has required amount of money

    "We have mulled over process of COVID-19 vaccine distribution and the amount required for it in terms of prioritization of population and the staggered immunization for this prioritization. In the meetings, we have calculated the amount required and currently, that amount is available," Bhushan claimed.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Latest
    India
    Coronavirus
    Serum Institute of India
    Adar Poonawalla

    Latest

    TikTok's existential crisis: What is the app's future TikTok
    #NewsBytesExplainer: Understanding parasocial relationships in showbiz—dangerous side of celebrity obsessions Bollywood
    Best cruiser bikes in India that suit different riding styles Latest Motorcycles
    IND vs AUS: Mitchell Starc stars with 3/49 in defeat Indian Cricket Team

    India

    When will India get 6G: Here's the telecom minister's response 6G Technology
    Varun Gandhi declines invitation to speak at Oxford Union debate Varun Gandhi
    What is ISRO's "Young Scientist" program and how to apply Indian Space Research Organisation (ISRO)
    Credit Suisse's crisis is more relevant to India: Know how Reserve Bank Of India (RBI)

    Coronavirus

    COVID-19 origin from raccoon dogs in China, not bats: Study COVID-19
    Cases of new unidentified COVID-19 variant reported in Israel Israel
    China to resume issuing visas to foreigners after 3 years China
    7th Pay Commission: Government employees may soon receive salary hikes Central Pay Commission

    Serum Institute of India

    Serum Institute seeks DCGI's approval for Covovax as booster dose Drugs Controller General of India
    India's 100 richest amassed $25bn more wealth in 2022: Forbes Gautam Adani
    Covishield manufacturer SII duped of Rs. 1 crore, 7 arrested Pune
    Covishield death: Bombay HC notice to Centre, Serum Institute, DCGI Bombay High Court

    Adar Poonawalla

    Is SII developing vaccine for monkeypox? Here's what Poonawalla said Vaccine
    Only faster COVID-19 vaccinations can end pandemic: Adar Poonawalla World Health Organization
    SII to launch COVID-19 vaccine for children in 6 months Serum Institute of India
    EU body says it didn't receive application for Covishield approval Europe

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023